Transformation Program: Increasing Scientific Rigor, Cost Reduction and Spend Transparency for Local Clinical Trials

Situation

• A Top 10 pharmaceutical company was missing the transparency of the medical spend – especially in the region & countries
• As part of a company-wide initiative, the focus was put on local clinical trials in the Medical Affairs division

SOLUTION

• Initial assessment of current issues revealed gaps in compliance, redundancy in studies across countries, non-targeted study design resulting in gaps in evidence generation, and lack of efficiencies
• A new medical governance body (Scientific Committee) has been formed to evaluate, prioritize and finally approve clinical trials that are planned on county level – KPIs have been defined to track success
• An evidence generation framework has been established to minimize redundancy and targeted study design

IMPACT

• 99 % of all local clinical studies were aligned with the evidence generation framework resulting in better study design, less redundancy, and increased compliance
• Measures put in place resulted in 8 % savings (medium double-digit Mio USD per year) and full transparency on country spend